scholarly journals Comparative Effectiveness Analysis Using Real World Evidence (RWE) and Applying a Causal Marginal Structural Model: the Case of Second-Line Treatment in Patients with Ovarian Cancer

2018 ◽  
Vol 21 ◽  
pp. S18
Author(s):  
U Siebert ◽  
F Kuehne ◽  
M Arvandi ◽  
LM Hess ◽  
DE Faries ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Real World ◽  
Comparative Effectiveness ◽  
Structural Model ◽  
Line Treatment ◽  
Second Line ◽  
Marginal Structural Model ◽  
Effectiveness Analysis ◽  
Real World Evidence ◽  
Comparative Effectiveness Analysis

scholarly journals Assessing Type and Impact of Biases Potentially Occurring when Analyzing Real World Evidence: The Case of Second Line Treatment for Ovarian Cancer

2018 ◽  
Vol 21 ◽  
pp. S213
Author(s):  
F Kuehne ◽  
M Arvandi ◽  
LM Hess ◽  
DE Faries ◽  
R Matteucci Gothe ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Real World ◽  
Line Treatment ◽  
Second Line ◽  
Real World Evidence

scholarly journals Real-world evidence: A review of clinical experience in metastatic gastric cancer second-line treatment with ramucirumab

2019 ◽  
Vol 16 (3) ◽  
Author(s):  
Miguel Quintana-Quintana ◽  
María Consuelo Díaz-Romero ◽  
Christian Patricio Camacho-Limas ◽  
Laura Torrecillas-Torres ◽  
Erika Ruiz-García ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinical Experience ◽  
Real World ◽  
Metastatic Gastric Cancer ◽  
Line Treatment ◽  
Second Line ◽  
Real World Evidence

scholarly journals Comparative effectiveness of trastuzumab emtansine versus lapatinib plus capecitabine for HER2+ metastatic breast cancer

2020 ◽  
Author(s):  
Sreeram V Ramagopalan ◽  
Riccardo Pisoni ◽  
Aleksandr Zenin ◽  
Lokendra Singh Rathore ◽  
Joshua Ray ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Metastatic Breast Cancer ◽  
Real World ◽  
Comparative Effectiveness ◽  
Metastatic Breast ◽  
World Population ◽  
Trastuzumab Emtansine ◽  
Line Treatment ◽  
Second Line

Aim: To investigate the comparative effectiveness of trastuzumab emtansine (T-DM1) in a real-world population of HER2+ metastatic breast cancer (mBC) patients. Materials and methods: The Flatiron Health database was used to identify a cohort of HER2+ mBC patients who received first-line trastuzumab treatment and T-DM1 or lapatinib plus capecitabine as second-line treatment. Overall survival was compared between the two groups. Results: Three hundred and forty-five patients with HER2+ mBC received second-line T-DM1 and 65 lapatinib plus capecitabine. Overall survival was longer in patients treated with T-DM1 than those treated with lapatinib plus capecitabine (adjusted hazard ratio: 0.61; 95% CI: 0.41–0.91). Conclusion: Real-world data supports the effectiveness of T-DM1 in the second-line treatment of HER2+ mBC patients.

Sign in / Sign up

Export Citation Format

Share Document